Erasca reports positive early data for cancer drug ERAS-0015

April 27, 2026 4:01 PM

Erasca Inc. (NASDAQ: ERAS) announced preliminary Phase 1 data for its experimental cancer drug ERAS-0015, showing response rates in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found